Raia Drogasil SA (RADLY)
4.90
-0.60
(-10.91%)
USD |
OTCM |
May 17, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 8.404B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -1.85% |
| Valuation | |
| PE Ratio | 38.84 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.161 |
| Price to Book Value | 6.944 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0097 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.4677 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 87.36% |
Profile
| Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries. |
| URL | https://www.rd.com.br/en |
| Investor Relations URL | https://ri.rd.com.br/ |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 18, 2024 |
Ratings
Profile
| Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries. |
| URL | https://www.rd.com.br/en |
| Investor Relations URL | https://ri.rd.com.br/ |
| HQ State/Province | N/A |
| Sector | |
| Industry | |
| Equity Style | Large Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Apr. 18, 2024 |